Cargando…

Fatigue after initiating rivaroxaban for venous thromboembolism

BACKGROUND: Rivaroxaban was the first new oral anticoagulant approved for treatment of venous thromboembolism (VTE). Clinical trials have shown that rivaroxaban is noninferior to conventional anticoagulation for VTE in efficacy and safety. Increased fatigue after the initiation of rivaroxaban has be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karlsvik, Tina Margrethe, Borgenvik, Thore Langfeldt, Aadalen, Mirjam, Utne, Kristin, Førsund, Eli, Jørgensen, Camilla Tøvik, Holst, René, Jelsness‐Jørgensen, Lars‐Petter, Ghanima, Waleed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Article: Thrombosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292653/ https://www.ncbi.nlm.nih.gov/pubmed/32548556 http://dx.doi.org/10.1002/rth2.12312

Ejemplares similares

Health-related quality of life after deep vein thrombosis
por: Utne, Kristin Kornelia, et al.
Publicado: (2016)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older
por: Ageno, Walter, et al.
Publicado: (2021)

Health-related quality of life after pulmonary embolism: a cross-sectional study
por: Tavoly, Mazdak, et al.
Publicado: (2016)

Detection of upper extremity deep vein thrombosis by magnetic resonance non‐contrast thrombus imaging
por: van Dam, Lisette F., et al.
Publicado: (2021)

Overall and abdominal obesity in relation to venous thromboembolism
por: Yuan, Shuai, et al.
Publicado: (2020)

Rivaroxaban treatment of cancer‐associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience
por: Soff, Gerald A., et al.
Publicado: (2019)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

Cancer‐associated venous thromboembolism: Incidence and features in a racially diverse population
por: Raskob, Gary E., et al.
Publicado: (2022)

Joint effect of myocardial infarction and obesity on the risk of venous thromboembolism: The Tromsø Study
por: Sejrup, Joakim K., et al.
Publicado: (2022)

Evaluation of the Khorana, PROTECHT, and 5‐SNP scores for prediction of venous thromboembolism in patients with cancer
por: Guman, Noori A. M., et al.
Publicado: (2021)

Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study
por: Giustozzi, Michela, et al.
Publicado: (2021)

Safety of using the combination of the Wells rule and D‐dimer test for excluding acute recurrent ipsilateral deep vein thrombosis
por: van Dam, Lisette F., et al.
Publicado: (2020)

D‐dimer to rule out venous thromboembolism during pregnancy: A systematic review and meta‐analysis
por: Bellesini, Marta, et al.
Publicado: (2021)

Pharmacokinetic modeling and simulation support for age‐ and weight‐adjusted dosing of dabigatran etexilate in children with venous thromboembolism
por: Röshammar, Daniel, et al.
Publicado: (2021)

Genetic risk and incident venous thromboembolism in middle‐aged and older adults following COVID‐19 vaccination
por: Xie, Junqing, et al.
Publicado: (2022)

Risk of recurrence in women with venous thromboembolism related to estrogen‐containing contraceptives: Systematic review and meta‐analysis
por: Wiegers, Hanke M. G., et al.
Publicado: (2022)

Elevated plasma levels of plasminogen activator inhibitor‐1 are associated with risk of future incident venous thromboembolism
por: Frischmuth, Tobias, et al.
Publicado: (2022)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

The venous thrombosis registry in Østfold Hospital (TROLL registry) ‐ design and cohort description
por: Jørgensen, Camilla Tøvik, et al.
Publicado: (2022)

Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta‐analysis
por: Mulder, Frits I., et al.
Publicado: (2020)

Awareness of venous thromboembolism among patients with cancer: Preliminary findings from a global initiative for World Thrombosis Day
por: Potere, Nicola, et al.
Publicado: (2022)

Pharmacological thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower limb immobilization after injury: systematic review and network meta‐analysis
por: Horner, Daniel, et al.
Publicado: (2019)

Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer
por: Becattini, Cecilia, et al.
Publicado: (2022)

The impact of body weight on rivaroxaban pharmacokinetics
por: Barsam, Sarah J., et al.
Publicado: (2017)

Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery—Systematic review and meta‐analysis
por: Presume, João, et al.
Publicado: (2022)

Fatigue as an Extra-Intestinal Manifestation of Celiac Disease: A Systematic Review
por: Jelsness-Jørgensen, Lars-Petter, et al.
Publicado: (2018)

Association between vitamin D and fatigue in patients with rheumatoid arthritis: a cross-sectional study
por: Jelsness-Jørgensen, Lars Petter, et al.
Publicado: (2020)

A qualitative study of patient experiences of decentralized acute healthcare services
por: Linqvist Leonardsen, Ann-Chatrin, et al.
Publicado: (2016)

Health‐related quality‐of‐life questionnaires for deep vein thrombosis and pulmonary embolism: A systematic review on questionnaire development and methodology
por: Asady, Elia, et al.
Publicado: (2021)

Unraveling a borderline antithrombin deficiency case with quantitative mass spectrometry
por: Kruijt, Mirjam, et al.
Publicado: (2021)

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023)

Evidence-base for aspirin as venous thromboembolic prophylaxis following joint replacement
por: Jameson, S. S., et al.
Publicado: (2014)

Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study
por: Hill, Jason B., et al.
Publicado: (2020)

Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
por: Carney, Brian J., et al.
Publicado: (2021)

Comparison of thromboembolism outcomes in patients with sickle cell disease prescribed hormonal contraception
por: Bala, Natasha S., et al.
Publicado: (2023)

Polygenic risk of major depressive disorder as a risk factor for venous thromboembolism
por: Ward, Joey, et al.
Publicado: (2023)

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry
por: Giannis, Dimitrios, et al.
Publicado: (2021)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials
por: Scheres, Luuk J. J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ltl3thand3l9ntstb6omn269ks